ReviewClinical interventions in aging2008
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Review in Clinical interventions in aging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 63 citations in OpenAlex.
- Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.BMC musculoskeletal disorders · 2017Trial
- An audit of the fracture liaison service at Helen Joseph Tertiary Hospital, Johannesburg, South Africa.Archives of osteoporosis · 2026Article
- Glycosaminoglycans in tissue regeneration: Insights into glycobiology and their biomedical application.Bioactive materials · 2026Review
- Micro/nano-structured titanium surfaces promote endothelial responses and angiogenic activity under zoledronic acid exposure.BMC oral health · 2026Article
- Osteo-inductive potential of homoeopathy potencies of Asafoetida on multipotent mesenchymal stem cells in vitro.3 Biotech · 2025Article
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- Use of an emulated trial to investigate the association between use of nitrogen-based bisphosphonates and risk of epithelial ovarian cancer.International journal of epidemiology · 2024Article
- Article
- Article
- Effect of Mechanical Stimuli and Zoledronic Acid on the Femoral Bone Morphology in Rats with Obesity and Limited Mobility.Journal of clinical medicine · 2022Article
- Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.Clinical oral investigations · 2022Article
- Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.Journal of the National Cancer Institute · 2022Article
- Article
- Review
- Alveolar socket healing in 5-lipoxygenase knockout aged female mice treated or not with high dose of zoledronic acid.Scientific reports · 2021Article
- Article
- Histomorphometric Evaluation of Peri-Implant Bone Response to Intravenous Administration of Zoledronate (ZometaMaterials (Basel, Switzerland) · 2020Article
- A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein-2 and zoledronic acid.Science advances · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.